Amgevita Indications/Uses

Rheumatoid Arthritis: AMGEVITA is indicated for reducing signs and symptoms, including major clinical response and clinical remission, inhibiting the progression of structural damage and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
AMGEVITA can be used alone or in combination with methotrexate or other disease modifying anti-rheumatic drugs (DMARDs).
Psoriatic Arthritis: AMGEVITA is indicated for reducing the signs and symptoms of active arthritis in patients with psoriatic arthritis, inhibiting the progression of structural damage, and improving physical function in patients with psoriatic arthritis.
AMGEVITA can be used alone or in combination with disease modifying anti-rheumatic drugs.
Axial Spondyloarthritis: Ankylosing Spondylitis: AMGEVITA is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.
Non-radiographic Axial spondyloarthritis (Axial Spondyloarthritis without radiographic evidence of AS): AMGEVITA is indicated for reducing signs and symptoms in patients with active non-radiographic axial spondyloarthritis (nr-axSpA) but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs.
Plaque Psoriasis: AMGEVITA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy and when other systemic therapies are medically less appropriate.
Crohn's Disease: AMGEVITA is indicated for the treatment of moderately to severely active Crohn's disease in adults patients who have inadequate response to conventional therapy. AMGEVITA is also indicated for treatment in adult patients with moderately to severely active Crohn's Disease who have lost response to or are intolerant to infliximab.
Ulcerative Colitis: AMGEVITA is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.
Hidradenitis Suppurativa: AMGEVITA is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adult patients with an inadequate response to conventional systemic HS therapy.
Uveitis: AMGEVITA is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate.
Paediatrics: Juvenile idiopathic arthritis: Polyarticular Juvenile Idiopathic Arthritis: AMGEVITA in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients aged above 2 years old who had an inadequate response to one or more disease modifying anti-rheumatic drugs (DMARDs). AMGEVITA can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.
Enthesitis-Related Arthritis: AMGEVITA is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy.
Pediatric Crohn's Disease: AMGEVITA is indicated for the treatment of moderately to severely active Crohn's disease in pediatric patients (6 to 17 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy, a corticosteroid, and an immunomodulator, or who are intolerant to or have contraindication for such therapies.
Paediatric Plaque Psoriasis: AMGEVITA is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapy.
Paediatric Uveitis: AMGEVITA is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom corticosteroid treatment is inappropriate.